Chronic inflammation and low-dose glucocorticoid effects on glucose metabolism in premenopausal females with rheumatoid arthritis free of conventional metabolic risk factors

Physiological Research

Volumn 62, Issue 1, 2013, Pages 75-83

  Penesova A ^a   Radikova Z ^a   Vlcek M ^a,b   Kerlik, J ^a   Lukac J ^c   Rovensky J ^c   Imrich, R ^a,b  

^a INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

^c NATIONAL INSTITUTE OF RHEUMATIC DISEASES   (Slovakia)

Author keywords

Glucocorticoid treatment; Glucose metabolism; Inflammation; Insulin sensitivity; Rheumatoid arthritis

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FATTY ACID; GLUCOCORTICOID; IL6 PROTEIN, HUMAN; INSULIN; INTERLEUKIN 6; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CASE CONTROL STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RESISTANCE; METABOLISM; PREMENOPAUSE; RHEUMATOID ARTHRITIS; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOCORTICOIDS; GLUCOSE TOLERANCE TEST; HUMANS; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; LINEAR MODELS; PREDNISONE; PREMENOPAUSE; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84876054542     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. CEDERHOLM J, WIBELL L, Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract 10: 167-175, 1990.
2. CHUNG CP, OESER A, SOLUS JF, GEBRETSADIK T, SHINTANI A, AVALOS I, SOKKA T, RAGGI P, PINCUS T, STEIN CM, Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 58: 2105-2112, 2008.
3. DA SILVA JA, JACOBS JW, KIRWAN JR, BOERS M, SAAG KG, INES LB, DE KONING EJ, BUTTGEREIT F, CUTOLO M, CAPELL H, RAU R, BIJLSMA JW, Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 65: 285-293, 2006.
4. DEL RINCON ID, WILLIAMS K, STERN MP, FREEMAN GL, ESCALANTE A, High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44: 2737-2745, 2001.
5. DESSEIN PH, JOFFE BI, Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 54: 2765-2775, 2006.
6. DESSEIN PH, JOFFE BI, STANWIX AE, CHRISTIAN BF, VELLER M, Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol 31: 867-874, 2004.
7. DESSEIN PH, TOBIAS M, VELLER MG, Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 33: 2425-2432, 2006.
8. FEBBRAIO MA, ROSE-JOHN S, PEDERSEN BK, Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases? Clin Pharmacol Ther 87: 396-398, 2010
9. FERNANDEZ-REAL JM, RICART W, Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24: 278-301, 2003.
10. GONZALEZ A, MARADIT KREMERS H, CROWSON CS, NICOLA PJ, DAVIS JM, THERNEAU TM, ROGER VL, GABRIEL SE, The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 56: 3583-3587, 2007.
11. HOTAMISLIGIL GS, SHARGILL NS, SPIEGELMAN BM, Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259: 87-91, 1993.
12. LA MONTAGNA G, CACCIAPUOTI F, BUONO R, MANZELLA D, MENNILLO GA, ARCIELLO A, VALENTINI G, PAOLISSO G, Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diab Vasc Dis Res 4: 130-135, 2007.
13. LIBBY P, Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 121: S21-S31, 2008.
14. MARADIT-KREMERS H, NICOLA PJ, CROWSON CS, BALLMAN KV, GABRIEL SE, Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52: 722-732, 2005.
15. MARI A, TURA A, PACINI G, KAUTZKY-WILLER A, FERRANNINI E, Relationships between insulin secretion after intravenous and oral glucose administration in subjects with glucose tolerance ranging from normal to overt diabetes. Diabet Med 25: 671-677, 2008.
16. MATSUDA M, DE FRONZO RA, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470, 1999.
17. MATTHEWS DR, HOSKER JP, RUDENSKI AS, NAYLOR BA, TREACHER DF, TURNER RC, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
18. MCKELLAR GE, MCCAREY DW, SATTAR N, MCINNES IB, Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol 6: 410-417, 2009.
19. MEUNE C, TOUZE E, TRINQUART L, ALLANORE Y, High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and metaanalysis. Arch Cardiovasc Dis 103: 253-261, 2010.
20. NARANJO A, SOKKA T, DESCALZO MA, CALVO-ALEN J, HORSLEV-PETERSEN K, LUUKKAINEN RK, COMBE B, BURMESTER GR, DEVLIN J, FERRACCIOLI G, MORELLI A, HOEKSTRA M, MAJDAN M, SADKIEWICZ S, BELMONTE M, HOLMQVIST AC, CHOY E, TUNC R, DIMIC A, BERGMAN M, TOLOZA S, PINCUS T; QUEST-RA GROUP, Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 10: R30, 2008.
21. PAMUK ON, UNLU E, CAKIR N, Role of insulin resistance in increased frequency of atherosclerosis detected by carotid ultrasonography in rheumatoid arthritis. J Rheumatol 33: 2447-2452, 2006.
22. PAOLISSO G, VALENTINI G, GIUGLIANO D, MARRAZZO G, TIRRI R, GALLO M, TIRRI G, VARRICCHIO M, D'ONOFRIO F, Evidence for peripheral impaired glucose handling in patients with connective tissue diseases. Metabolism 40: 902-907, 1991.
23. PEDERSEN BK, FEBBRAIO M, Muscle-derived interleukin-6 - a possible link between skeletal muscle, adipose tissue, liver, and brain. Brain Behav Immun 19: 371-376, 2005.
24. PEMBERTON PW, AHMAD Y, BODILL H, LOKKO D, HIDER SL, YATES AP, WALKER MG, LAING I, BRUCE IN, Biomarkers of oxidant stress, insulin sensitivity and endothelial activation in rheumatoid arthritis: a cross-sectional study of their association with accelerated atherosclerosis. BMC Res Notes 2: 83, 2009.
25. ROCHA VZ, LIBBY P, Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 6: 399-409, 2009.
26. ROSENVINGE A, KROGH-MADSEN R, BASLUND B, PEDERSEN BK, Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol 36: 91-96, 2007.
27. SADAGURSKI M, NORQUAY L, FARHANG J, D'AQUINO K, COPPS K, WHITE MF, Human IL6 enhances leptin action in mice. Diabetologia 53: 525-535, 2010.
28. SATTAR N, GAW A, SCHERBAKOVA O, FORD I, O'REILLY DS, HAFFNER SM, ISLES C, MACFARLANE PW, PACKARD CJ, COBBE SM, SHEPHERD J, Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108: 414-419, 2003a.
29. SATTAR N, MCCAREY DW, CAPELL H, MCINNES IB, Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108: 2957-2963, 2003b.
30. SHOELSON E, LEE J, GOLDFINE AB, Inflammation and insulin resistance. J Clin Invest 116: 1793-1801, 2006.
31. STOUTHARD JM, ROMIJN JA, VAN DER POLL T, ENDERT E, KLEIN S, BAKKER PJ, VEENHOF CH, SAUERWEIN HP, Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol 268: E813-E819, 1995.
32. SVENSON KL, POLLARE T, LITHELL H, HALLGREN R, Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism 37: 125-130, 1988.
33. TANAKA T, KANDA T, MCMANUS BM, KANAI H, AKIYAMA H, SEKIGUCHI K, YOKOYAMA T, KURABAYASHI M, Overexpression of interleukin-6 aggravates viral myocarditis: impaired increase in tumor necrosis factor-alpha. J Mol Cell Cardiol 33: 1627-1635, 2001.
34. TOMS TE, PANOULAS VF, DOUGLAS KM, GRIFFITHS HR, KITAS GD, Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a crosssectional study. Arthritis Res Ther 10: R145, 2008.
35. VAN RAALTE DH, OUWENS DM, DIAMANT M, Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 39: 81-93, 2009
36. VAN RAALTE DH, BRANDS M, VAN DER ZIJL NJ, MUSKIET MH, POUWELS PJ, ACKERMANS MT, SAUERWEIN HP, SERLIE MJ, DIAMANT M, Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia 54: 2103-2112, 2011a.
37. VAN RAALTE DH, VAN GENUGTEN RE, LINSSEN MM, OUWENS DM, DIAMANT M, Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 34: 412-417, 2011b.
38. WALLACE TM, LEVY JC, MATTHEWS DR, Use and abuse of HOMA modeling. Diabetes Care 27: 1487-1495, 2004.
39. WALLENIUS V, WALLENIUS K, AHREN B, RUDLING M, CARLSTEN H, DICKSON SL, OHLSSON C, JANSSON JO, Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8: 75-79, 2002.
40. WANG L, FENG G, Rheumatoid arthritis increases the risk of coronary heart disease via vascular endothelial injuries. Med Hypotheses 63: 442-445, 2004.
41. YUDKIN JS, KUMARI M, HUMPHRIES SE, MOHAMED-ALI V, Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148: 209-214, 2000